Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective post remission treatment for leukemia, resulting in lower relapse rates than alternative therapies. However, it is limited by the lack of suitable human leukocyte antigen (HLA) matched donors and high rates of transplant-related morbidity and mortality. Cord blood transplantation (CBT) and haploidentical SCT (haplo-SCT) expand the potential donor pool but are also associated with major complications. Co-infusion of third-party donor stem cellswith a CBT/haplo-SCT, which is called “dual transplantation,” has been reportedto improve the outcome of HSCTby accelerating hematopoietic reconstitution and reducing the incidence of graft-versus-host disease (GVHD). In addition, infusion of HLA-mismatched donor granulocyte colony-stimulating factor–mobilized donor peripheral blood stem cellsafter chemotherapy, the so called “microtransplantation”, has been shown to promote the graft–versus-leukemiaeffect and hasten hematopoietic recovery without amplifying GVHD. Herein, we review recent advances in stem cell therapy for leukemia with a specific focus on dual transplantation and microtransplantation.
Keywords: Allogeneic hematopoietic stem cell transplantation, cord blood, haploidentical, microtransplantation.
Current Stem Cell Research & Therapy
Title:Advances in Stem Cell Therapy for Leukemia
Volume: 11 Issue: 2
Author(s): Hong Tian, Qi Qu, Liming Liu and Depei Wu
Affiliation:
Keywords: Allogeneic hematopoietic stem cell transplantation, cord blood, haploidentical, microtransplantation.
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective post remission treatment for leukemia, resulting in lower relapse rates than alternative therapies. However, it is limited by the lack of suitable human leukocyte antigen (HLA) matched donors and high rates of transplant-related morbidity and mortality. Cord blood transplantation (CBT) and haploidentical SCT (haplo-SCT) expand the potential donor pool but are also associated with major complications. Co-infusion of third-party donor stem cellswith a CBT/haplo-SCT, which is called “dual transplantation,” has been reportedto improve the outcome of HSCTby accelerating hematopoietic reconstitution and reducing the incidence of graft-versus-host disease (GVHD). In addition, infusion of HLA-mismatched donor granulocyte colony-stimulating factor–mobilized donor peripheral blood stem cellsafter chemotherapy, the so called “microtransplantation”, has been shown to promote the graft–versus-leukemiaeffect and hasten hematopoietic recovery without amplifying GVHD. Herein, we review recent advances in stem cell therapy for leukemia with a specific focus on dual transplantation and microtransplantation.
Export Options
About this article
Cite this article as:
Tian Hong, Qu Qi, Liu Liming and Wu Depei, Advances in Stem Cell Therapy for Leukemia, Current Stem Cell Research & Therapy 2016; 11 (2) . https://dx.doi.org/10.2174/1574888X10666151019120217
DOI https://dx.doi.org/10.2174/1574888X10666151019120217 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Tyrosine Kinase Inhibitors on Growth and Bone Metabolism in
Children with Haematologic Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets Pharmacogenetics of Therapy in Inflammatory Bowel Disease Patients
Current Pharmacogenomics Signaling Mechanism(S) of Reactive Oxygen Species in Epithelial-Mesenchymal Transition Reminiscent of Cancer Stem Cells in Tumor Progression
Current Stem Cell Research & Therapy Foamy Virus Vectors: An Awaited Alternative to Gammaretro- and Lentiviral Vectors
Current Gene Therapy Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Never Sleep with Baby? Or Keep Me Close But Keep Me Safe: Eliminating Inappropriate “Safe Infant Sleep” Rhetoric in the United States
Current Pediatric Reviews Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Current Cancer Drug Targets Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Exploring and Exploiting Biologically Relevant Chemical Space
Current Drug Targets